Clinical utility of phosphatidylethanol to detect underreported alcohol use and enhance steatotic liver disease subclassification
Federica Tavaglione(Università Campus Bio-Medico), Rohit Loomba(University of California San Diego), Veeral Ajmera(University of California San Diego), Seema Singh(University of Mississippi Medical Center), Lisa Richards(University of California San Diego), Egbert Madamba(University of California San Diego), Ricki Bettencourt(University of California San Diego), Luis Antonio Díaz(Pontificia Universidad Católica de Chile)
Cited by 49
Related Papers
A Universal Gut-Microbiome-Derived Signature Predicts Cirrhosis
|Cell Metabolism|2020|342
A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes
|Journal of Hepatology|2022|310
TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial
|Gastroenterology|2021|216